Tigecycline Usage for Severe Infections in the Pediatric Intensive Care Unit

Abstract

Objective To evaluate the effectiveness and safety of using tigecycline as a salvage therapy in critically ill children who did not respond to other antibiotics.

Methods We conducted a retrospective cohort analysis that included children who received tigecycline for at least 48 hours and four doses during their pediatric intensive care unit admission. Demographic and clinical features of the subjects were evaluated through a comprehensive review of medical records. The effectiveness of tigecycline was assessed by thoroughly evaluating clinical and microbiological outcomes.

Results During the study period, 72 pediatric patients with 88 episodes of infection received tigecycline according to antimicrobial susceptibility in 62.5% of cases and empirically in 37.5%. The median duration of tigecycline therapy was 10 days (range, 2–33 days). Klebsiella pneumoniae (n = 17, 30.9%) was the most frequently isolated pathogen, followed by Acinetobacter baumannii (n = 10, 18.1%). Ventilator-associated pneumonia was the most common infection (n = 29). Of the 55 isolated pathogens, 43 were multidrug-resistant (MDR), and 2 were extensively drug-resistant (XDR) gram-negative bacteria. Clinical response and microbiological clearance were achieved in 42 and 50.9% of episodes, respectively. The overall mortality was 40.9%, with an attributable mortality rate of 29.5%.

Conclusion Tigecycline could be used as a salvage therapy for critically ill pediatric patients infected with MDR or XDR pathogens in the lack of alternative treatment options.

Keywords

tigecycline - pediatric intensive care unit - multidrug-resistant - extensively drug-resistant

Publication History

Received: 28 November 2023

Accepted: 26 June 2024

Article published online:
02 August 2024

• References

• 1 Curcio D, Vargas SW, Ugarte Ubiergo S. et al; Latin American Tigecycline Initial Use Registry. Tigecycline treatment of critically ill patients: the LatinUser experience. Curr Clin Pharmacol 2011; 6 (01) 18-25
• 2 Ozkaya-Parlakay A, Gulhan B, Kanik-Yuksek S. et al. Tigecycline therapy in pediatric patients with multidrug resistant bacteremia. Enferm Infecc Microbiol Clin (Engl Ed) 2020; 38 (10) 471-473
• 3 Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52 (03) 203-208
• 4 Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 2010; 10: 287
• 5 Food and Drug Administration. Accessed January 19, 2024, at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021821s026s031lbl.pdf
• 6 Basak S, Singh P, Rajurkar M. Multidrug-resistant and extensively drug-resistant bacteria: a study. J Pathog 2016; 2016: 4065603
• 7 Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36 (05) 309-332
• 8 Ye S, Zhang C, Lin S. Preliminary experience with tigecycline treatment for severe infection in children. Eur J Pediatr 2018; 177 (10) 1489-1496
• 9 Poulakou G, Kontopidou FV, Paramythiotou E. et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect 2009; 58 (04) 273-284
• 10 Song Y, Hu L, Shu Q. et al. Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery. Int J Infect Dis 2018; 75: 82-88
• 11 Wyeth Pharmaceuticals LLC. Philadelphia; 2005 TYGACIL—tigecycline injection, powder, lyophilized, for solution. http://labeling.pfizer.com/showlabeling.aspx?id=491
• 12 Maseda E, Denis SE, Riquelme A, Gilsanz F. Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections. Rev Esp Quimioter 2013; 26 (01) 56-63
• 13 Zhu ZY, Yang JF, Ni YH, Ye WF, Wang J, Wu ML. Retrospective analysis of tigecycline shows that it may be an option for children with severe infections. Acta Paediatr 2016; 105 (10) e480-e484
• 14 Chung DR, Song JH, Kim SH. et al; Asian Network for Surveillance of Resistant Pathogens Study Group. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011; 184 (12) 1409-1417
• 15 Aygun F, Aygun FD, Varol F. et al. Infections with carbapenem-resistant gram-negative bacteria are a serious problem among critically ill children: a single-centre retrospective study. Pathogens 2019; 8 (02) 69
• 16 El-Nawawy A, Ashraf GA, Antonios MAM, Meheissen MA, El-Alfy MMR. Incidence of multidrug-resistant organism among children admitted to pediatric intensive care unit in a developing country. Microb Drug Resist 2018; 24 (08) 1198-1206
• 17 Chiotos K, Hayes M, Gerber JS, Tamma PD. Treatment of carbapenem-resistant Enterobacteriaceae infections in children. J Pediatric Infect Dis Soc 2020; 9 (01) 56-66
• 18 Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab 2009; 10 (01) 13-21
• 19 Tumbarello M, Viale P, Viscoli C. et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55 (07) 943-950
• 20 Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents 2014; 44 (01) 1-7
• 21 Wu X, Zhu Y, Chen Q. et al. Tigecycline therapy for nosocomial pneumonia due to carbapenem-resistant gram-negative bacteria in critically ill patients who received inappropriate initial antibiotic treatment: a retrospective case study. Biomed Res Int 2016; 2016: 8395268
• 22 Purdy J, Jouve S, Yan JL. et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther 2012; 34 (02) 496-507.e1
• 23 Lin S, Liang L, Zhang C, Ye S. Preliminary experience of tigecycline treatment in critically ill children with ventilator-associated pneumonia. J Int Med Res 2020; 48 (01) 300060518760435
• 24 Iosifidis E, Violaki A, Michalopoulou E. et al. Use of tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria. J Pediatric Infect Dis Soc 2017; 6 (02) 123-128
• 25 Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46 (04) 567-570
• 26 Ye JJ, Lin HS, Kuo AJ. et al. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J Infect 2011; 63 (05) 351-361
• 27 Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M. et al; REIPI/ESGBIS/INCREMENT Investigators. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 2017; 17 (07) 726-734
• 28 European Medicines Agency. Tigecycline, Summary of Product Characteristics. Accessed January 3, 2016, at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000644/WC500044508.pdf
• 29 U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. Accessed January 2, 2016, at: http://www.fda.gov/drugs/drugsafety/ucm369580.htm